Beyond Air, Inc. Stock News

Beyond Air (XAIR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Beyond Air, Inc. (XAIR) Q3 2024 Earnings Call Transcript

Beyond Air, Inc. (XAIR) came out with a quarterly loss of $0.50 per share versus the Zacks Consensus Estimate of a loss of $0.61. This compares to loss of $0.43 per share a year ago.

Beyond Air, Inc. (NASDAQ:XAIR ) Q2 2024 Earnings Conference Call November 13, 2023 4:30 PM ET Company Participants Edward Barger - Head of Investor Relations Steve Lisi - Chairman and Chief Executive

GARDEN CITY, N.Y., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”) a commercial stage medical device and biopharmaceutical company focused on

GARDEN CITY, N.Y. and HAMILTON, Bermuda, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Beyond Cancer, Ltd., an affiliate of Beyond Air, Inc. (NASDAQ: XAIR) that is developing ultra-high concentration nitric oxide

The realm of penny stocks, often characterized by their affordable price tag, has become a hotspot for investors eager to seize the stock market's opportunities. These stocks, typically valued under $

Beyond Air, Inc. (NASDAQ:XAIR ) Q1 2024 Earnings Conference Call August 10, 2023 4:30 PM ET Company Participants Edward Barger - Head of Investor Relations Steve Lisi - Chairman and Chief Executive Of

Beyond Air, Inc. (XAIR) came out with a quarterly loss of $0.45 per share versus the Zacks Consensus Estimate of a loss of $0.46. This compares to loss of $0.37 per share a year ago.

GARDEN CITY, N.Y., July 24, 2023 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”) a commercial stage medical device and biopharmaceutical company focused on

Today, we take a look at an interesting small-cap medical device concern called Beyond Air, Inc. The company is just rolling out its first approved product and has other assets in development. However

Beyond Air, Inc. (NASDAQ:XAIR ) Q4 2023 Earnings Conference Call June 22, 2023 4:30 PM ET Company Participants Edward Barger - Head of Investor Relations Steve Lisi - Chairman and Chief Executive Offi

Beyond Air, Inc. (XAIR) came out with a quarterly loss of $0.67 per share versus the Zacks Consensus Estimate of a loss of $0.44. This compares to loss of $0.26 per share a year ago.

GARDEN CITY, N.Y., May 16, 2023 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a commercial stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for

According to the Insider Cluster Buys Screen, a Premium feature of GuruFocus, five stocks that have high number of unique insider buys over the past three months are Air Transport Services Group Inc.